Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Short-term Investments (2016 - 2025)

Capricor Therapeutics has reported Short-term Investments over the past 12 years, most recently at $30.3 million for Q4 2025.

  • Quarterly results put Short-term Investments at $30.3 million for Q4 2025, down 78.41% from a year ago — trailing twelve months through Dec 2025 was $30.3 million (down 78.41% YoY), and the annual figure for FY2025 was $30.3 million, down 78.41%.
  • Short-term Investments for Q4 2025 was $30.3 million at Capricor Therapeutics, down from $79.1 million in the prior quarter.
  • Over the last five years, Short-term Investments for CAPR hit a ceiling of $140.2 million in Q4 2024 and a floor of $16.7 million in Q3 2024.
  • Median Short-term Investments over the past 4 years was $33.7 million (2024), compared with a mean of $49.7 million.
  • Biggest five-year swings in Short-term Investments: skyrocketed 465.6% in 2024 and later crashed 78.41% in 2025.
  • Capricor Therapeutics' Short-term Investments stood at $31.8 million in 2022, then fell by 22.08% to $24.8 million in 2023, then skyrocketed by 465.6% to $140.2 million in 2024, then crashed by 78.41% to $30.3 million in 2025.
  • The last three reported values for Short-term Investments were $30.3 million (Q4 2025), $79.1 million (Q3 2025), and $99.6 million (Q2 2025) per Business Quant data.